MedTrace Logo

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

NCT00004070 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2017-04-20

No results posted yet for this study

Summary

Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to make the body build an immune response to kill more tumor cells.

Conditions

Interventions

BIOLOGICAL

IL-12

Sponsors & Collaborators

Principal Investigators

  • A. Dimitrios Colevas, MD · NCI-Investigational Drug Branch

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Primary Completion
2000-11-30
Completion
2000-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004070 on ClinicalTrials.gov